Alkegen Backed by Clearlake Capital, Announces New Aerogel Technology
19.4.2022 17:30:00 EEST | Business Wire | Press release
Alkegen, a leading specialty materials platform creating transformational materials, today introduced its latest proprietary technology, AlkeGel™ by Alkegen. AlkeGel is a next generation flexible aerogel material designed for electric vehicle and battery fire protection applications, along with other industrial thermal management uses. AlkeGel from Alkegen offers exceptionally low thermal conductivity and dustiness, superior thermal performance and a reduction in insulation thicknesses compared to competing insulation products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005730/en/
AlkeGel is Alkegen’s first step into fiber-based aerogel composite materials for critical applications in battery and electric vehicle safety, fire protection and industrial thermal management segments. Alkegen is the new company launched in January following the acquisition of Lydall Materials by Unifrax. Alkegen is a one-of-a-kind specialty materials platform dedicated to human health and sustainability. Alkegen is a global leader in transformative high growth battery technologies, filtration media and specialty insulation with a deep history of vertically integrated manufacturing at large scale to provide solutions for advanced industries including electric vehicles, filtration, aerospace, and chemical processing. The company expects production for AlkeGel materials to come online in mid-2022 with plans to build thousands of tons of long-term manufacturing capacity.
”AlkeGel is the latest development from our long-standing tradition of innovating unique material technologies to create superior new products and solutions for our customers’ greatest challenges,” explained Chad Cannan, Senior Vice President and Chief Innovation Officer at Alkegen. “These composite aerogel materials offer excellent insulation properties, and include advanced proprietary technology features we’ve developed with our novel aerogel process. AlkeGel creates performance advantages for our customers in terms of improved product handling, a wide range of shapes and sizes and step change EV fire safety relative to other high performance insulations on the market today. Alkegen’s AlkeGel technology coupled with the broadest set of large scale global end product forming and finishing operations marks a new horizon for these exciting materials,” said Cannan.
“This transformational aerogel portfolio presents numerous opportunities for Alkegen with applications spanning EV lithium ion battery protection, cryogenic applications along with the broader industrial and fire protection markets. AlkeGel products add to our complete portfolio of robust electric vehicle and battery solutions which include AGM separator materials, novel silicon anode materials, lithium ion glass separators, interstitial thermal runaway barriers, and battery compartment fire protection systems,” added John Dandolph, President and CEO of Alkegen.
Alkegen will be available to discuss their innovative new aerogel materials during the 2022 AABC Europe Show June 13, in Mainz, and The Battery Show June 28, in Stuttgart, Germany. Interested attendees can sign up for sessions with our Alkegen Battery Group experts to meet during the conferences by contacting us at info@alkegen.com.
About Alkegen
Alkegen, formerly Unifrax and Lydall Materials, creates high performance specialty materials used in advanced applications including electric vehicles, energy storage, filtration, fire protection and high-temperature insulation, among many others. Alkegen products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our mission of helping the world breathe easier, live greener and go further than ever before. Alkegen has 75 manufacturing facilities operating in 12 countries and employs 9,000+ employees globally. More information is available at www.alkegen.com.
About Clearlake
Clearlake Capital Group, L.P. is an investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $30 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005730/en/
Contact information
Media:
For Alkegen:
Deborah L. Myers
Director, Marketing Communication
dmyers@alkegen.com
716.768.6465
For Clearlake:
Jennifer Hurson
jhurson@lambert.com
845-507-0571
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom